Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.

Saved in:
Bibliographic Details
Title: Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Authors: Fürstenau M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Weiss J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Giza A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Franzen F; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Schneider C; Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany., Tausch E; Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany., Stilgenbauer S; Division of CLL, Department of Internal Medicine III, University of Ulm, Ulm, Germany., Ritgen M; Department of Internal Medicine II, Faculty of Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany., Schilhabel A; Department of Internal Medicine II, Faculty of Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany., Brüggemann M; Department of Internal Medicine II, Faculty of Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany., Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Cramer P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Dusseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Oct 03; Vol. 28 (19), pp. 4203-4211.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-22-0433